Michael A Noble

Title: The Innovations of Inventor Michael A. Noble in Prenyltransferase and Aldehyde Dehydrogenase Variants

Introduction: Michael A. Noble, an inventive mind located in San Diego, CA, has made significant strides in the field of biochemistry and synthetic biology. With a total of two patents to his name, Noble's work focuses on the development of novel prenyltransferase variants and aldehyde dehydrogenase variants that open up new avenues for the production of valuable aromatic compounds and potential therapeutic applications.

Latest Patents: Noble's most recent patents include innovative breakthroughs in the production of prenylated aromatic compounds. His patent on prenyltransferase variants describes non-natural variants that demonstrate at least a two-fold increase in the formation rate of cannabinoids, including cannabigerolic acid and cannabigerol. These variants also exhibit selective production of specific isomers, which can be expressed in engineered microbes for the synthesis of compounds like 3-GOLA, used in developing therapeutic compositions. Additionally, his work on aldehyde dehydrogenase variants provides methods to produce key compounds such as 3-hydroxybutyraldehyde and 1,4-butanediol, showcasing his versatility and innovative approach in bioprocessing.

Career Highlights: Michael A. Noble is a valuable member of Genomatica, Inc., a company known for its focus on sustainable chemical processes. His work combines scientific inquiry and practical application, contributing to advancements in green chemistry and the production of valuable chemicals through biologically engineered pathways.

Collaborations: Throughout his career, Noble has collaborated with talented colleagues such as Kevin G. Hoff and Cara Ann Tracewell. These partnerships reflect his commitment to teamwork and innovation, fueling developments that push the boundaries of current scientific understanding.

Conclusion: Michael A. Noble epitomizes the spirit of innovation in the scientific community. With his patents on prenyltransferase and aldehyde dehydrogenase variants, he is paving the way for groundbreaking applications in the production of cannabinoids and other valuable compounds. His work, facilitated by collaborations within Genomatica, Inc., demonstrates the important intersection of research and real-world application, contributing to advancements that hold promise for both industry and healthcare.